Morton Coleman

List of Publications by Year
in descending order

118 papers	2,579 citations	430874 18 h-index	197818 49 g-index
118 all docs	118 docs citations	118 times ranked	3058 citing authors

#	Article	IF	Citations
1	Three-year follow-up of treatment-naÃ¯ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 2015, 125, 2497-2506.	1.4	618
2	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncology, The, 2014, 15, 48-58.	10.7	438
3	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood, 2017, 129, 2224-2232.	1.4	243
4	Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer, 2002, 94, 879-888.	4.1	187
5	CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood, 2016, 127, 3360-3368.	1.4	89
6	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Advances, 2020, 4, 5773-5784.	5.2	67
7	Prednisone, etoposide, procarbazine, and cyclophosphamide (PEPâ€C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Lowâ€dose metronomic, multidrug therapy. Cancer, 2008, 112, 2228-2232.	4.1	57
8	Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Seminars in Oncology, 2003, 30, 270-274.	2.2	56
9	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica, 2021, 106, 2364-2373.	3.5	53
10	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget, 2016, 7, 4598-4610.	1.8	53
11	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical Cancer Research, 2021, 27, 6323-6332.	7.0	42
12	Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia and Lymphoma, 2008, 49, 447-450.	1.3	38
13	Epratuzumab: targeting B-cell malignancies through CD22. Clinical Cancer Research, 2003, 9, 3991S-4S.	7.0	34
14	Once-weekly ofatumumab in untreated or relapsed WaldenstrÃ¶m's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematology,the, 2017, 4, e24-e34.	4.6	33
15	An association between chronic neutrophilic leukaemia and multiple myeloma with a study of cobalaminâ€binding proteins. British Journal of Haematology, 1986, 63, 173-180.	2.5	30
16	Anticoagulation and high dose liver radiation.A preliminary report. Cancer, 1979, 43, 174-181.	4.1	25
17	Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia and Lymphoma, 2015, 56, 3065-3070.	1.3	20
18	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2027-2038.	2.4	20

#	Article	IF	Citations
19	Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leukemia Research, 2014, 38, 517-524.	0.8	18
20	Treatment of prolymphocytic leukemia. Cancer, 1982, 50, 1687-1689.	4.1	17
21	Involved-site radiotherapy for Helicobacter pyloriâ€“independent gastric MALT lymphoma: 26 years of experience with 178 patients. Blood Advances, 2021, 5, 1830-1836.	5.2	17
22	Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leukemia and Lymphoma, 2015, 56, 2870-2875.	1.3	15
23	Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).. Journal of Clinical Oncology, 2018, 36, 7549-7549.	1.6	15
24	High dose methotrexate with citrovorum factor in adult resistant lymphoma. Cancer, 1977, 40, 2823-2828.	4.1	14
25	Early18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas. Cancer, 2006, 107, 1425-1428.	4.1	14
26	Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology, 2012, 17, s90-s92.	1.5	14
27	Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 107-113.	0.4	14
28	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer Journal, 2021, 11, 101.	6.2	14
29	A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,. Blood, 2011, 118, 3701-3701.	1.4	13
30	ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. Blood, 2012, 120, 77-77.	1.4	11
31	Ki-1 Skin Lymphoproliferative Disorders: Management with Radiation Therapy. Cancer Investigation, 1997, 15, 91-97.	1.3	10
32	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 930-937.	2.0	10
33	Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Advances, 2019, 3, 603-611.	5.2	10
34	ClaPD (Clarithromycin/[BiaxinÂ®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. Blood, 2011, 118, 635-635.	1.4	10
35	MAGNIFY phase IIIb interim analysis of induction R² followed by maintenance in relapsed/refractory indolent NHL.. Journal of Clinical Oncology, 2020, 38, 8046-8046.	1.6	10
36	A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.. Blood, 2010, 116, 1795-1795.	1.4	9

#	Article	IF	Citations
37	Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report. Blood, 2014, 124, 625-625.	1.4	9
38	Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2019, 37, 7530-7530.	1.6	9
39	Oral Lymphomatoid papulosis type C: A diagnostic pitfall, often confused with T-cell lymphoma. Annals of Diagnostic Pathology, 2017, 31, 50-55.	1.3	8
40	Comparison of fluorineâ€18 fluorodeoxyglucose positron emission tomography and Gaâ€67 scintigraphy in evaluation of lymphoma. Cancer, 2002, 94, 879-888.	4.1	8
41	Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).. Blood, 2005, 106, 2574-2574.	1.4	8
42	At-101 Induces Apoptosis Waldenstrol̂m Macroglobulinemia Cells Resistant to Bortezomib.. Blood, 2009, 114, 2861-2861.	1.4	8
43	HAC-cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating Chemotherapy With Intensification. Cancer, 1985, 55, 2342-2347.	4.1	7
44	Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 825-833.	0.4	7
45	An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 400-407.e1.	0.4	7
46	Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 2751-2751.	1.4	7
47	Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma. Blood, 2013, 122, 1954-1954.	1.4	7
48	Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation. Blood, 2015, 126, 500-500.	1.4	7
49	Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood, 2021, 138, 812-812.	1.4	7
50	Incidental discovery at radical mastectomy of inapparent hodgkin's disease in long term survivors. Cancer, 1978, 42, 318-325.	4.1	6
51	Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma. Blood, 2013, 122, 1955-1955.	1.4	6
52	Response rate to lenalidomide plus rituximab (R²) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.. Journal of Clinical Oncology, 2018, 36, 7516-7516.	1.6	6
53	Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, andcis-platinum (HAC): Results in both untreated and previously treated patients. Medical and Pediatric Oncology, 1984, 12, 17-24.	1.0	5
54	Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). Blood, 2018, 132, 4144-4144.	1.4	5

#	Article	IF	Citations
55	A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.. Blood, 2009, 114, 1877-1877.	1.4	5
56	The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial. Blood, 2013, 122, 4393-4393.	1.4	5
57	The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant WaldenstrÃ¶ms Macroglobulinemia. Blood, 2014, 124, 1689-1689.	1.4	5
58	Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2014, 124, 4754-4754.	1.4	5
59	High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma. Blood, 2015, 126, 4258-4258.	1.4	5
60	Vindesine: A phase II study in childhood malignancies-A report for cancer and leukemia group B. Medical and Pediatric Oncology, 1982, 10, 35-43.	1.0	4
61	Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). International Journal of Cancer, 1988, 41, 829-831.	5.1	4
62	Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 539-545.	4.1	4
63	Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial. Blood, 2019, 134, 694-694.	1.4	4
64	CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).. Blood, 2009, 114, 2682-2682.	1.4	4
65	Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib. Blood, 2015, 126, 4232-4232.	1.4	4
66	Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8036-8036.	1.6	4
67	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. Blood, 2015, 126, 703-703.	1.4	4
68	Administration of a complex chemotherapy regimen: Inpatient versus outpatient treatment. Medical and Pediatric Oncology, 1983, 11, 333-335.	1.0	3
69	Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. Annals of Diagnostic Pathology, 2018, 37, 57-61.	1.3	3
70	Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance. Blood, 2020, 136, 24-25.	1.4	3
71	Newly-Diagnosed Multiple Myeloma. Blood, 2013, 122, 3216-3216.	1.4	3
72	A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL. Blood, 2013, 122, 4914-4914.	1.4	3

#	Article	IF	Citations
73	Acquired in Vitro Resistance to Ibrutinib Is Associated with Transcriptional Re-Programming and Sustained Survival Signaling in WaldenstrÃ¶ms Macroglobulinemia and Mantle Cell Lymphoma, Independent of BTK Cys481 Mutation. Blood, 2014, 124, 2250-2250.	1.4	3
74	Therapeutic Sensitivity of CD20- WaldenstrÃ¶ms Macroglobulinemia Cells Is Determined By Underlying Genomic and Epigenetic Events. Blood, 2014, 124, 3115-3115.	1.4	3
75	Targeted Disruption of USP14 and UCHL5 with the Novel Deubiquitinase Enzyme (DUB) Inhibitor, VLX1570, Induces Immense Proteotoxicity and Cell Death in Malignant Plasma Cells. Blood, 2014, 124, 3116-3116.	1.4	3
76	Interim FDG PET/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL).. Journal of Clinical Oncology, 2013, 31, 8555-8555.	1.6	3
77	BTK Inhibition Targets in Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity.. Blood, 2012, 120, 2903-2903.	1.4	3
78	Lenalidomide in renal insufficiency â€“ balancing the risks and benefits: response to Borrello. British Journal of Haematology, 2009, 144, 447-448.	2.5	2
79	Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL. Blood, 2012, 120, 3706-3706.	1.4	2
80	Inhibition Of The Deubiquitinating Enzymes UCHL5 and USP14 Is Lethal To WaldenstrÃ¶ms Macroglobulinemia Cells. Blood, 2013, 122, 1823-1823.	1.4	2
81	Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).. Journal of Clinical Oncology, 2017, 35, TPS7579-TPS7579.	1.6	2
82	Methylation Patterns in WaldenstrÃ¶ms Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and Cepba Family of Transcription Factors. Blood, 2014, 124, 3551-3551.	1.4	2
83	Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. American Journal of Hematology, 2021, 96, 1554-1562.	4.1	1
84	Thalidomide Is Active Alone and in Combination with Fludarabine in Fludarabine-Relapsed and Refractory Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 4835-4835.	1.4	1
85	Stromal Incorporation of VEGFR-1+, CD68+ and Î±-SMA+ Hemangiogenic Cells Correlates with Histologic Subtype in Non-Hodgkinâ€™s Lymphoma.. Blood, 2005, 106, 1930-1930.	1.4	1
86	Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. Blood, 2007, 110, 3024-3024.	1.4	1
87	Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.. Blood, 2010, 116, 1785-1785.	1.4	1
88	A Comparison of Chemotherapy + G-CSF Versus Plerixafor (MozobilÂ®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide. Blood, 2010, 116, 2258-2258.	1.4	1
89	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma. Blood, 2011, 118, 2042-2042.	1.4	1
90	Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,. Blood, 2011, 118, 3712-3712.	1.4	1

#	Article	IF	Citations
91	Newly-Diagnosed Multiple Myeloma. Blood, 2014, 124, 4761-4761.	1.4	1
92	Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102).. Journal of Clinical Oncology, 2017, 35, TPS7578-TPS7578.	1.6	1
93	Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.. Blood, 2007, 110, 2737-2737.	1.4	1
94	MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells. Blood, 2010, 116, 785-785.	1.4	1
95	Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities. Blood, 2010, 116, 3561-3561.	1.4	1
96	Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy. Blood, 2012, 120, 1636-1636.	1.4	1
97	The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 2016-2016.	1.4	1
98	Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma. Blood, 2015, 126, 2991-2991.	1.4	1
99	Subgroup Analyses of Elderly Patients Aged â‰¥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood, 2020, 136, 30-31.	1.4	1
100	Primary Non-Hodgkin's Lymphoma of Bone. Cancer Investigation, 1998, 16, 616-617.	1.3	0
101	Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.. Blood, 2004, 104, 1497-1497.	1.4	0
102	Targeting Early Events of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Suppressed Syk and PLCÎ³2 Activities Predict Apoptotic Response of Leukemic Cells to Dasatinib. Blood, 2008, 112, 5023-5023.	1.4	0
103	ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 4686-4686.	1.4	0
104	The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.. Blood, 2009, 114, 4349-4349.	1.4	0
105	Levels of Circulating Endothelial Cells and Endothelial Progenitors Correlate with Disease Status and Treatment Response in Human Lymphoma Subtypes of CLL and MCL.. Blood, 2009, 114, 3941-3941.	1.4	0
106	Activity of SYK and PLCÎ³2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib.. Blood, 2009, 114, 1249-1249.	1.4	0
107	Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.. Blood, 2009, 114, 2311-2311.	1.4	0
108	Updated Report of T-Bird (thalidomide, clarithromycin/[BiaxinÂ®], lenalidomide/[RevlimidÂ®],) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	1.4	0

#	Article	IF	Citations
109	T-Bird (thalidomide, clarithromycin/[BiaxinÂ®], lenalidomide/[RevlimidÂ®], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma. Blood, 2011, 118, 2937-2937.	1.4	0
110	Prognostic value of post-inductionÂPET/CTÂin untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).. Journal of Clinical Oncology, 2012, 30, e21006-e21006.	1.6	0
111	Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population. Blood, 2012, 120, 4269-4269.	1.4	0
112	The Deubiquitinating Enzymes Of The 19S Proteasome Offer Novel Therapeutic Opportunity In Bortezomib Resistant WaldenstrÃ¶ms Macroglobulinemia. Blood, 2013, 122, 4426-4426.	1.4	0
113	Prevention of Intravascular Thrombus Formation on Plastic Catheters with Heparin-Benzalkonium Complex: in Vivo and in Vitro Studies. Thrombosis and Haemostasis, 1979, 41, 537-543.	3.4	0
114	Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone). Blood, 2014, 124, 5778-5778.	1.4	0
115	Higher BTK-Dependent Cell Proliferation in Unmutated Chronic Lymphocytic Leukemia Confers Increased Sensitivity to Ibrutinib. Blood, 2015, 126, 5296-5296.	1.4	0
116	An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma. Blood, 2015, 126, 3027-3027.	1.4	0
117	Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution. Blood, 2019, 134, 5644-5644.	1.4	0
118	Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma. Blood, 2019, 134, 4399-4399.	1.4	0